pre-IPO PHARMA

COMPANY OVERVIEW

Navitor Pharmaceuticals, Inc. is the leader in the development of mTORC1-targeted therapeutics designed to help patients live longer and healthier lives. The Company’s proprietary platform enables true modulation of mTORC1, the gatekeeper of cellular metabolism and renewal, with the first-ever absolutely selective mTORC1 inhibition and the unique ability for mTORC1 activation.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Kidney Disease
  • Neurological Disorders

  • WEBSITE

    https://www.navitorpharma.com


    CAREER WEBSITE

    https://www.navitorpharma.com/careers/careers/


    SOCIAL MEDIA


    INVESTORS

    atlas-venture brace-pharma-capital jjdc nan-fung-group polaris-partners remeditex-ventures sanofi-ventures sr-one


    PRESS RELEASES


    Feb 2, 2022

    Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc.


    Feb 2, 2022

    Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc.


    Apr 16, 2019

    Navitor Pharmaceuticals Announces Peer-Reviewed Publication in Journal of Clinical Investigation Highlighting Rapid Antidepressant Effects of NV-5138


    Mar 11, 2019

    Navitor Pharmaceuticals Announces Peer-Reviewed Publication Detailing the Discovery and Development of NV-5138


    Jan 24, 2019

    Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, a Novel mTORC1 Activator in Patients with Treatment-Resistant Depression


    For More Press Releases


    Google Analytics Alternative